On July 30, Israel had administered a third dose of Pfizer's mRNA Covid vaccine amid the recent surge in the country due to the Delta variant
According to a new study, a booster dose of Pfizer's COVID-19 vaccine can prevent both infections and severe illness in adults older than 60 years shortly after the injection. This new study was conducted in Israel.
On July 30, Israel had administered a third dose of Pfizer's mRNA Covid vaccine amid the recent surge in the country due to the Delta variant. It was first approved for persons who were 60 years of age or older and who had received a second dose of vaccine at least five months earlier.
A study published in the New England Journal of Medicine showed that the rates of confirmed COVID-19 and severe illness were substantially lower among those who received a booster (third) dose of the BNT162b2 vaccine
For the study, the team extracted data from July 30 to August 31, from the Israeli Ministry of Health database regarding 1,137,804 persons who were 60 years of age or older and had been fully vaccinated (that is, had received two doses of BNT162b2) at least 5 months earlier.
At least 12 days after the booster dose, the rate of infection was eleven-fold lower and of severe disease nearly twenty-fold lower in those who received a booster compared with those who had received only two doses, the study showed.
For the study, the team extracted data from July 30 to August 31, from the Israeli Ministry of Health database regarding 1,137,804 persons who were 60 years of age or older and had been fully vaccinated (that is, had received two doses of BNT162b2) at least 5 months earlier.
At least 12 days after the booster dose, the rate of infection was eleven-fold lower and of severe disease nearly twenty-fold lower in those who received a booster compared with those who had received only two doses, the study showed.
No comments:
Post a Comment